당뇨병 환자의 운동

Exercise in Diabetes Mellitus

가	-	
2240	-	
Yun - Jun Yang, M.D.	-	
Department of Family Medicine	_	500
Inje University College of Medicine, Ilsan Paik Hospital	4040	
E - mail : johnyang@ilsanpaik.ac.kr	1919 -	

Abstract

xercise and diet control are essential for the management of diabetes mellitus. Beneficial effects of exercise have been established. Exercises improve the control of glucose level, decrease cardiac risk factors and prevent type 2 diabetes mellitus. Exercise can cause hypoglycemia or hyperglycemia, cardiac attack, dehydration, foot problems and aggravation of diabetic complications. Pre - exercise medical evaluation is needed to prevent the unwanted effect of exercise. Diabetic patients who have ketonuria and high blood glucose level(more than 250mg/dL) should postpone exercise until the problems are solved. Diabetic patients should enjoy their activities and do warming up and cool down exercise. Vigorous aerobic exercise, 60~85% of maximal oxygen uptake, 20~60 minutes at a time, 3~5 times a week is recommended. Moderate aerobic exercise, 40~60% of maximal oxygen uptake, more than 30 minutes at a time, over 5 times a week is also recommended instead. Muscle strengthening exercises, 2~3 times a week should be added. To prevent hypoglycemia during exercise, the dose of insulin should be reduced. If the patient suffer from hypoglycemic symptom, he or she should take glucose immediately. Therefore diabetic patients should carry some simple carbohydrates. To prevent dehydration during exercise, proper hydration and clothes must be prepared. Wearing well fitting shoes, frequent check up for any wounds on foot are needed to prevent diabetic foot complications. Diabetic patients have the rights to have good quality of life. Regular proper exercise could improve their quality of life.

Keywords : Diabetes Mellitus; Exercise; Aerobic exercise; Hypoglycemia; Dehydration

(2).

 $(3 \sim 5)$.

2

2

1)

1926

1997

1. 4) 1. Lower blood glucose concentrations during and after exercise 2. Lower basal and postprandial insulin concentrations 3. Improve insulin sensitivity 4. Lower glycated hemoglobin levels(type 2) 5. Improve lipid profile: Decrease triglyceride. Slightly decrease low - density lipoprotein cholesterol Increase high - density lipoprotein cholesterol 6. Improvement in mild - to - moderate hypertension 5) (Fibrinolysis) 7. Increase energy expenditure: 가 Adjunct to diet for weight reduction. Increased fat loss. Preservation of lean body mass. 2 8. Cardiovascular conditioning plasminogen activator inhibitor - 1 9. Increase strength and flexibility 10. Improve sense of well - being and quality of life . Plasminogen activator 2) tissue plaminogen activator(TPA) inhibitor - 1 2 가 가 6) 가 가 2 7) 가가 2 (6). 3) 2 $(7 \sim 11)$. triglyceride - rich VLDL 가 2 2 HDL **VDRL** HDL HDL 가 48

٠	48			가	
가		(12).		가	(15).
2. 1			,		
	(macrovascu	lar disease)			
가 ,					
1		(13).		가	
		1	가 가		(glycogen syn
		,	thetase)가 가		
(A1c)					
•					
;	가 . 1		1		6~15
				24	
(14).					
가					
	,	,			
					. 1
					•
•					
			2		
			,		
		10%가	,		
	,	50%			
	50%가				
100%	100%가				
•	(alvonas salv	oio)			가
	(glycogenoly:	515)			71
	,			•	

2.

 Hypoglycemia, if treated with insulin or oral agents Exercise induced hypoglycemia Late - onset postexercise hypoglycemia Hyperglycemia after very strenuous exercise Hyperglycemia and ketosis in insulin - deficient patient Precipitation or exacerbation of cardiovascular disease Angina pectoris, Myocardial infarction, Arrhythmias, S Worsening of long - term complications of diabetes m Proliferative retinopathy: Vitreous hemorrhage, Retir 	Sudden death ellitus	가 . 10 10% 가	,
 Nephropathy: Increased proteinuria Peripheral neuropathy: Soft tissue and joint injuries Autonomic neuropathy: Decreased cardiovascular creased maximum aerobic of to dehydration. Postural hyp 	capacity. Impaired response)
		UKPDS	
		(www.d	tu.ox.ac.uk/
1.	riskengine /downlo		
가	,	가	
가 ,		가 (5).	
	> 40 (
2.) > 30		
,	* 10	, , ,	
	(dyslipidemia	а),	,
	()	
3.	*	, ,	
	*		
, ,	*		
1)		(AACE)	40

3.

Level of DR	Acceptable activity	Discouraged activity	Ocular reevaluation
No DR	Dictated by medical status	Dictated by medical status	12 months
Mild NPDR	Dictated by medical status	Dictated by medical status	6~12 months
Moderate NPDR	Dictated by medical status	Activities that dramatically elevate blood pressure (Power lifting, Heavy Valsalva)	4~6 months
Severe NPDR	Dictated by medical status	Activities that substantially increase systolic blood pressure, Valsalva maneuvers and active jarring (Boxing, Heavy competitive sports)	2~4 months (may require laser surgery)
PDR	Low impact, cardiovascular conditioning(Swimming, Walking, Low - impact aerobics, Stationary cycling, Endurance exercises)	Strenuous activities, Valsalva maneuvers pounding or jarring (Weight lifting, Jogging, High - impact aerobics, Racquet sports, strenuous trumpet playing)	1~2 months (may require laser surgery)

DR: diabetic retinopathy

NPDR: nonproliferative diabetic retinopathy

가 2) (16). ST - T 가 가 (radionuclide stress testing) (dorsalis pedis artery, tibialis poste-60% rior artery) (fore-가 가 foot) (doppler pressure) 3) (exercise ischemic threshold) 가 (strenuous exercise) vitreous hemorrhage

traction retinal detachment가

4.) 가 Contraindicated exercise Recommended exercise Treadmill Swimming (가, Prolonged walking Bicycling Walking on uneven surface Arm exercises 가 Jogging Rowing Step exercises Chair exercises Other non - weight - bearing exercises 4) thallium myocardial scintigraphy가 5) 가 monofilament , 5.07(10g) monofilament 가 (low impact) (4). 250mg/dL 6) 300mg/dL 100 20mmHg

5.			
Long - Term Contraindications(exercise adjustment required) * Autonomic neuropathy with orthostatic hypotension after exercise ir position - bicycling and swimming are OK, but running and hiking st avoided. * Severe peripheral neuropathy of the feet, which could lead to Charco	hould be 1.		
nerative joint disease in the lower extremity with weight - bearing exerc* * Retinopathy - anaerobic exercise involving sudden stress must be avoid			
Temporary Contraindications(correction of condition required) * Blood glucose level 300 mg/dl * Ketonuria > 36 mg/dl or level of beta - hydroxybutyric acid > 9 mg/dl * Hypoglycemia before exercise	•	3	30
* Dehydration	20		
300mg/dL		가	
5 .			フ
	, . , 가		
•	71		
5~10 , , (5)	가 . 가). 3	,	가
		8~10	
5~10 . 8.	~10 3	가	

가

	6.	(60)				
leto e cit.		Relative intensity					,
Intensity	VO _{2max} (%)	Maximal heart rate(%)	RP	E*	40	~ 60%	
Very light	< 20	< 35	< 10()	55 ~ 70%		150
Light	20~39	35~54	10~11()	(30	5)
Moderate	40~59	55~69	12~13()			
Hard	60~84	70~89	14~16()			
Very hard	> 85	> 90	17~19()	(Rate of	perceived exer-
Maximal	100	100	20()	tion, RP	E)	
RPE: Borg rating	g of relative perceived e	exertion			RPE 12~	13	
					40 ~ 60	%	(6).
(5	5).		3.				
				5~	10	,	20~60
	,			,	5~	10	
		, ,	4.				
,							3 ,
	, ,						,
	,	가			5		
	가	· 가 .			· ·		·
	·	·	5.	가			
2.			0.	- 1			
	60~85%가		3		, 2~4	,	
	180mmHg	·			, <u>2</u> . 가 .		
70~9		•	,	,			, 7
70 - 0	70 70	•					, ,
		г 220 -		•			30
		ر - 220		_			30
	가	٦L		5	,		
	71	가	,			•	(ICT)
	•		2				(IGT)
							150

```
(19)
        7.
                                                                              100mg/dL
               : 가
                                 10~15
                     60~85%
                                         70~90%
                                     5~10
                                              가
       20~60 .
                               ), 3~5 (
                      2~3 (
                                                                 (metformin,
                                                                                 - glucosidase
                                                                 inhibitors, thiazolidinediones)
1.
                                                                      30
                                                                              15~30g
                            가
               가
                                                                                        가
                           가
                      가
                                                                      1
                                                      가
                                                                                 가
                                           가
                                                       가
                                                                100mg/dl
                                                                                      15~30g
                                                          60 ~ 120kcal
                           가
                                                 2~3
```

	가				ty)				가
		가				가			
	•	*1							
						,			
	•					가	,	(callus)	,
2.					,	71	가		
가									
	가		가						
2	500℃		,	30				,	
1~2 ,	15		,	,				,	
						가			가
30	,	70%							
				가	,				가
	•								
								가	
		가							
					가		,	7	'
3.					71			ŕ	,
			가						
	4		•	,			·		
,	,	,	•			•	가	,	
				Charcot					
foot		,		(deformi-					

가 . . 가 가 가 가 가

.♥

1. Fahey PJ, Stallkamp ET, Kwatra S. The athlete with type I Diabetes: managing insulin, diet and exercise. American Family Physician 1996; 53: 1611 - 7

- Boule NG, HaddadE, Kenny GP, Wells GA, Siga RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta - analysis of controlled clinical trials.
 JAMA 2001: 286: 1218 - 27
- Eriksson J, Taimela S, Esiksson K. Resistance training in the treatment of non - insulin - dependent diabetes mellitus. Int J Sports Med 1997; 18: 242 - 6
- 4. Ivy JL, Role of exercise training in the prevention and treatment of insulin resistance and non insulin dependent diabetes mellitus. Sports Med 1997; 24: 321 36
- Signal RJ, Wasserman DH, Kenny GP, Castaneda Sceppa C. Physical activity/exercise and type 2 diabetes. Diabetic care 2004; 27: 2518 - 39
- Horton ES, ed Exercise. In Therapy for Diabetes Mellitus and related Disorders. 2nd ed. Alexandria: American Diabetes Association, Inc., 1994: 107 - 15
- 7. Pan XR, Li GW, Wang JX, Uang WY, An ZX, Howard BV, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537 - 44
- Lindstrom J, Louheranta A, Mannein M, Rastas M, Salminen V, Tuomilehto J, et al. The Finnish Diabetes Prevention Study(DPS): lifestyle intervention and 3 year results on diet and physical activity. Diabetes Care 2003; 26: 3230 6
- Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Eng J Med 2002; 346: 393 - 403
- Diabetes Prevention Program Research Group. The Diabetes Prevention Program(DPP): description of lifestyle intervention. Diabetes Care 2002; 25: 2165 - 71
- 11. Eriksson KF, Lindgarde F. No excess 12 year mortality in men with impaired glucose tolerance who participated in the Malmo Prevention trial with diet and exercise. Diabetologia 1998; 41: 1010 - 6
- 12. Sato Y, Iguchi A, Sakamoto N. Biochemical determination of

- training effects using insulin clamp technique. Horm Metb Res 1984: 16: 483 - 6
- American diabetes association. International Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183 - 97
- 14. Albright AL Diabetes. In Wikgren S, et al. eds. ACSM's Exercise Management for Persons with Chronic Diseases and Disabilities. Champaign: Human Kinetics, 1997: 94 100
- McArdle WD, Katch FI, et al. eds. Exercise physiology. 4th ed.
 Baltimore: Williams & Wilkins, 1996: 372 7

- Diabetes medical guidelines task force. AACE diabetes guidelines. Endocr Pract 2002; 8(Suppl 1): 41 73
- 17. Devlin JT, Ruderman N. Diabetes and exercise: the risk benefit profile. In: The Health Professional's Guide to Diabetes and Exercise. Alexandria: American Diabetes Association, 1995: 3 4
- American diabetes association. Physical activity / exercise and diabetes mellitus. Diabetic care 2003; 26(Suppl): S73 - 7
- Campaign BN. Exercise and diabetes mellitus. In ACSM's guidelines for exercise testing and prescription, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2000: 277 - 84

